---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-26-000112"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2026-08-03T12:11:28+00:00"
generated_at: "2026-08-03T12:15:04.909700+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Autolus raises FY2026 AUCATZYL revenue guidance to $140-150M, secures up to $250M credit facility

## Summary
- Preliminary Q2 2026 AUCATZYL net product revenue ~$45M, up ~70% QoQ and >100% YoY.
- FY2026 net product revenue guidance raised to $140-150M from $120-135M.
- Gross margin improved to ~35% in H1 2026 from negative ~20% in H2 2025.
- Entered five-year interest-only credit facility with Perceptive Advisors for up to $250M; initial $75M funded.
- Cash runway extended into Q2 2028; additional $150M available upon revenue milestones.

## SEC filing metadata
- accession: 0001730463-26-000112
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2026-08-03T12:11:28+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000112/0001730463-26-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000112/autl-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-26-000112
- JSON: https://secwatch.observer/filing/0001730463-26-000112.json
- Plain text: https://secwatch.observer/filing/0001730463-26-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.